Xeris Biopharma Strategy and Business Model

Executive Overview

Xeris Biopharma is a Chicago-based specialty pharmaceutical company focused on endocrinology, diabetes, and selected rare diseases. Founded in 2005, the company built its model around formulation technologies designed to keep injectable medicines ready to use and stable at room temperature, avoiding the reconstitution steps that often complicate emergency or chronic therapy. That science underpins Gvoke, Xeris’s glucagon rescue treatment for severe hypoglycemia. The 2021 acquisition of Strongbridge Biopharma broadened the portfolio with Keveyis for primary periodic paralysis and Recorlev for endogenous Cushing’s syndrome, shifting Xeris from a one-product diabetes company into a multi-product specialty-pharma platform. As of FY2024, Xeris reported revenue of #N/A. Commercially, the business remains heavily U.S.-weighted and depends on specialist prescribing, payer access, and patient identification in relatively small but attractive markets. Strategically, Xeris is trying to do two things at once: scale its current brands into a more durable cash-generating portfolio and use its formulation platforms to create additional internal pipeline assets or partnership revenue.

Xeris Biopharma at a Glance

Logo
Common name	Xeris Biopharma
Full legal name	Xeris Biopharma Holdings, Inc.
Headquarters	Chicago, Illinois, United States
Ownership	Public company
Ticker	XERS
Exchange	NASDAQ
Market Cap	$1.24B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2005; initial public offering in 2018; Gvoke pre-filled syringe approval in 2019; Gvoke HypoPen approval in 2020; Strongbridge Biopharma acquisition and Recorlev approval in 2021
Industry or industries	Specialty biopharmaceuticals; endocrinology; diabetes; rare disease therapeutics; neurology
Key products or services	Gvoke, Recorlev, Keveyis, XeriJect and XeriSol formulation platforms
Geographic footprint	Primarily United States, with selective partnered activity outside the U.S.
Business segments as officially reported	One reportable segment as of FY2024
Company website	https://www.xerispharma.com

1. What Is the Strategy of Xeris Biopharma?

Based on Xeris’s public filings, investor presentations, and earnings commentary through FY2024, the company’s strategy is best understood as a focused specialty-pharma play built around differentiated formulation science, niche commercial execution, and selective portfolio expansion. Using the Playing to Win framework:

1a. What is the winning aspiration of Xeris Biopharma?

Xeris’s winning aspiration appears to be to build a durable, profitable specialty pharmaceutical company that can turn difficult-to-formulate medicines into easier-to-use products and then commercialize them effectively in focused endocrine, diabetes, and rare-disease markets. In public messaging through 2024, management tied that aspiration to continued revenue growth, improved operating leverage, and a path toward sustained profitability and cash generation. The bigger strategic point is that Xeris does not want to remain a single-asset biotech; it wants to be a repeatable commercial platform.
1b. Where does Xeris Biopharma play?

Xeris plays in a relatively narrow set of markets where formulation convenience, specialist selling, and orphan-disease economics can matter. Its core commercial markets are severe hypoglycemia rescue, endogenous Cushing’s syndrome, and primary periodic paralysis. Geographically, the company is primarily U.S.-focused. Channel-wise, it plays through specialist physicians, wholesalers, retail pharmacies, specialty pharmacies, and reimbursement support rather than broad mass-market distribution. In development, it also plays in injectable reformulations and follow-on product concepts that fit its XeriJect and XeriSol technology platforms.
1c. How does Xeris Biopharma plan to win?

Xeris is not trying to win through scale or low cost. It is trying to win through product differentiation and focused execution. With Gvoke, the differentiation is usability: a ready-to-use liquid glucagon product that removes the reconstitution burden common in older rescue kits. With Recorlev and Keveyis, the play is specialist focus in small markets where dedicated commercial attention, patient support, and physician education can matter more than sheer salesforce size. More broadly, Xeris tries to make its formulation technology an economic asset twice over: first through its own products and second through pipeline or partnership opportunities.
1d. What capabilities must Xeris Biopharma have in place?

The critical capabilities are applied formulation science, drug-device and human-factors development, regulatory execution, rare-disease and endocrinology commercialization, market-access management, pharmacovigilance, and disciplined third-party manufacturing oversight. Because Xeris uses external supply partners, vendor management and quality systems are also strategic capabilities, not just back-office functions. The company additionally needs strong patient-services and specialty-pharmacy coordination because access and adherence can determine commercial success in these categories.
1e. What management systems does Xeris Biopharma require?

Xeris needs management systems that track prescription demand, payer coverage, gross-to-net adjustments, patient onboarding, safety monitoring, inventory, and cash usage with precision. Stage-gated portfolio review is especially important because the company must balance spending across marketed brands, pipeline assets such as XP-8121, and technology-platform opportunities. In a small commercial biopharma, governance around capital allocation, quality compliance, and launch discipline is a large part of strategy execution.

2. What Are the Current Strategic Initiatives of Xeris Biopharma?

In public materials through FY2024, Xeris’s strategic agenda centered on scaling its three marketed products, advancing a focused pipeline, and improving financial durability.

Expand Gvoke adoption in severe hypoglycemia. Xeris has continued to position Gvoke around ease of use, speed, and readiness versus legacy rescue options. Execution priorities appear to include prescriber education, payer access, retail pharmacy pull-through, and broader awareness among diabetes care teams and caregivers.
Build Recorlev in endogenous Cushing’s syndrome. Recorlev is a key growth asset because the treated market is small, specialist-driven, and still underdiagnosed. Xeris’s work here appears to involve specialist targeting, disease-awareness and patient-identification support, reimbursement navigation, and disciplined medical monitoring.
Protect and optimize Keveyis. Keveyis is a small orphan-drug franchise, but it can provide relatively stable specialty revenue. The initiative is less about mass expansion and more about maintaining prescriber relationships, adherence, and patient continuity in a niche indication.
Advance XP-8121 and other platform-enabled pipeline assets. Through 2024, Xeris highlighted XP-8121, its once-weekly subcutaneous levothyroxine candidate, as an important internal development program. The strategic logic is clear: use formulation technology to improve dosing convenience in a large endocrine category while keeping development focused.
Monetize formulation technology beyond current products. Xeris has long described XeriJect and XeriSol as platforms, not just internal tools. That makes business development, licensing, or co-development a continuing strategic initiative even if product sales remain the dominant revenue source.
Improve operating leverage and liquidity. Management commentary through 2024 repeatedly emphasized balancing growth with financial discipline. For Xeris, that means better absorption of commercial overhead, prioritization of the highest-return R&D spend, and tighter control of working capital and supply-chain execution.

3. What Is the Business Model of Xeris Biopharma?

Xeris’s business model is primarily a branded prescription-pharmaceutical model, supplemented by smaller streams that can come from partnerships, royalties, licensing, or technology-related arrangements.

What customers actually buy. Patients do not buy “formulation technology” directly; they buy branded therapies prescribed by specialists or diabetes providers. The core commercial products are Gvoke, Recorlev, and Keveyis.
Recurring or repeat-driven versus one-time. The revenue base is repeat-driven rather than subscription-like. Recorlev and Keveyis are chronic-use products, so refill persistence matters. Gvoke is a rescue product, but it can still generate repeat demand through refills, replacement, and ongoing preparedness behavior among at-risk patients.
Revenue model. The main revenue line is net product sales after rebates, discounts, copay assistance, chargebacks, returns reserves, and other gross-to-net adjustments. A secondary layer can come from royalty, milestone, licensing, or supply revenue tied to partnered programs or ex-U.S. rights.
How pricing power works. Xeris has some pricing leverage because it sells branded specialty products, including orphan therapies. But realized pricing is constrained by payer negotiations, coverage decisions, patient affordability programs, and government discounts. In other words, list price is not the same as net price.
Why the business mix matters. A larger share of chronic rare-disease revenue can make the portfolio more predictable than a single rescue drug alone. At the same time, Gvoke broadens the commercial base and helps support fixed overhead. The mix between established cash-generating brands and growth-stage brands is therefore strategically important.
What drives gross margin, operating margin, and cash generation. Gross margin depends on product mix, manufacturing scale, contract economics, and gross-to-net deductions. Operating margin is heavily influenced by salesforce productivity, medical and regulatory overhead, and R&D intensity relative to revenue. Cash generation improves when commercial growth outpaces launch and development spending.

4. What Products and/or Services Does Xeris Biopharma Sell?

As of FY2024, Xeris’s commercial portfolio centered on three marketed brands and a proprietary formulation platform that supports pipeline and partnership opportunities.

Gvoke. Gvoke is Xeris’s ready-to-use liquid glucagon rescue therapy for severe hypoglycemia. Its strategic importance comes from convenience and usability, especially compared with older glucagon kits that require reconstitution before use. The franchise includes device-based presentations such as an auto-injector and pre-filled syringe.
Recorlev. Recorlev is levoketoconazole for endogenous Cushing’s syndrome in adults for whom surgery is not an option or has not been curative. This is a chronic specialty product sold into a small, high-value endocrinology market and is one of Xeris’s main growth assets.
Keveyis. Keveyis is dichlorphenamide for primary periodic paralysis. It serves a rare disease population and appears to be strategically important as a durable specialty revenue stream with limited direct branded competition.
XeriJect and XeriSol formulation platforms. These are not mass-market products sold like drugs, but they are important strategic assets. They can support internal development, reformulation programs, and potential partnerships.
Pipeline programs. XP-8121, a once-weekly subcutaneous levothyroxine candidate, is the clearest example of how Xeris is trying to turn formulation capability into future product value.

Broadly, Gvoke and Keveyis appear to provide much of the portfolio’s current commercial base, while Recorlev and XP-8121 carry significant growth importance.

5. What Are the Key Competitors or Peers of Xeris Biopharma?

Xeris’s competitive set varies by product, so there is no single peer group that captures the entire company. The most relevant competitors and substitutes include:

Amphastar Pharmaceuticals. Amphastar competes in severe hypoglycemia rescue through glucagon products including Baqsimi nasal glucagon and injectable options.
Zealand Pharma / MannKind. Zegalogue (dasiglucagon) is another ready-to-use rescue option in severe hypoglycemia and competes with Gvoke for specialist attention and payer access.
Corcept Therapeutics. Corcept’s Korlym is an established therapy used in part of the Cushing’s treatment pathway and competes with Recorlev for endocrinologist mindshare.
Recordati Rare Diseases. Recordati markets Isturisa, a direct branded competitor in Cushing’s disease.
Novartis. Novartis markets Signifor and Signifor LAR, which also compete in parts of the Cushing’s treatment landscape.
Generic acetazolamide manufacturers. These are not direct branded peers to Keveyis, but off-label acetazolamide can function as a practical substitute for some periodic paralysis patients.

At the corporate level, Xeris is also comparable to small commercial-stage specialty-pharma companies that rely on a handful of niche brands, focused salesforces, and selective business development rather than blockbuster scale.

6. What Is the Marketing Strategy of Xeris Biopharma?

Xeris’s marketing strategy is specialist, access-oriented, and condition-specific. It does not need broad consumer reach in the way a large primary-care drug company might. Instead, it needs the right prescribers, payers, pharmacies, and patient-support workflows.

For Gvoke, marketing appears to emphasize usability, convenience, and preparedness. The target audience includes endocrinologists, diabetes specialists, diabetes educators, and caregivers who influence whether rescue glucagon is prescribed proactively. For Recorlev and Keveyis, the marketing task is even more targeted: building awareness among a relatively small number of specialists, supporting diagnosis and referral pathways, and helping patients navigate reimbursement and therapy initiation.

In practice, medical affairs, reimbursement support, and field education are at least as important as classical brand advertising. Marketing is therefore a supporting capability rather than the primary source of competitive advantage; the bigger differentiators are product design, specialty focus, and execution in narrow markets.

7. What Are the Key Customer Segments of Xeris Biopharma?

Xeris serves a concentrated set of customer segments tied to its three branded products.

Patients and caregivers managing severe hypoglycemia risk. This is the core end-market for Gvoke, particularly insulin-using patients who need an emergency rescue option.
Endocrinologists, diabetologists, and diabetes care teams. These clinicians are major prescribers and influencers for Gvoke and Recorlev.
Rare-disease specialists. Endocrinologists treating Cushing’s syndrome and neurologists or neuromuscular specialists seeing primary periodic paralysis patients are critical for Recorlev and Keveyis.
Payers, pharmacy benefit managers, and government reimbursement programs. They are not the end users, but they strongly affect access, net pricing, and prescription conversion.
Wholesalers, retail pharmacies, specialty pharmacies, and specialty distributors. These channel partners determine how efficiently products reach patients and how smoothly patient onboarding occurs.

Xeris is not diversified across dozens of therapeutic areas. Its revenue is concentrated in a small number of specialist end markets, which can support strong focus but also creates product and indication concentration risk.

8. What Is the Sales Model of Xeris Biopharma?

Xeris uses a specialty-pharma sales model built around direct field promotion to targeted prescribers, supported by payer access work, patient services, and channel coordination.

Direct physician selling. Xeris promotes its products to endocrinologists, diabetes specialists, and other relevant prescribers through a focused sales organization rather than a broad primary-care footprint.
Retail and wholesale channels. Gvoke reaches patients through retail pharmacy channels and wholesalers, making formulary access, prescription fill rates, and pharmacy execution important.
Specialty distribution and specialty pharmacy. Recorlev and Keveyis fit a more tightly managed specialty model, where benefits investigation, prior authorization, patient onboarding, and ongoing support can materially affect conversion and adherence.
Partner-led ex-U.S. commercialization where relevant. Outside the United States, Xeris has generally appeared more inclined to use partners than to build a large direct commercial infrastructure.

This channel structure gives Xeris relatively high customer intimacy in its chosen markets, but it also means growth depends on execution in a small number of high-value relationships rather than sheer volume. That creates useful opportunities for consultants in salesforce design, specialty-pharmacy optimization, and gross-to-net improvement.

9. In What Geographies Does Xeris Biopharma Operate?

Xeris’s operating and commercial footprint is concentrated in the United States. The company is headquartered in Chicago, Illinois, and its core commercial infrastructure is built around the U.S. regulatory, payer, specialty-pharmacy, and prescriber environment.

As of FY2024, Xeris did not resemble a globally diversified big pharma company with a large owned sales force across many countries. Its international activity appears more selective and partner-led, particularly where local commercialization can be outsourced more efficiently than building country-by-country infrastructure.

Operationally, Xeris also relies on third-party manufacturing and supply partners rather than a broad owned plant network. That means its geographic footprint should be understood less as a map of owned factories and more as a U.S.-centered commercial model supported by a distributed external supply base.

10. Who Are the Owners of Xeris Biopharma?

Xeris Biopharma is a publicly traded company on Nasdaq. As of the 2024 proxy period, ownership was dispersed, with institutional investors such as BlackRock and The Vanguard Group among notable holders, and no controlling shareholder was publicly disclosed. The company is not family-controlled or government-owned.

11. How Is Xeris Biopharma Organized?

Xeris Biopharma Holdings, Inc. is the listed parent company. As of FY2024, Xeris reported one operating and reportable segment, so investors should not expect the kind of segment-level disclosure seen at larger diversified pharmaceutical companies.

Practically, the company appears organized around:

Commercial brands: Gvoke, Recorlev, and Keveyis
Research and development: formulation technology, pipeline development, clinical and regulatory work
Medical, quality, and safety functions: medical affairs, pharmacovigilance, quality assurance, and compliance
Corporate support functions: market access, supply chain, finance, legal, and human resources

That is a typical structure for a small commercial-stage biopharma: centralized support functions with brand-specific commercial focus and a relatively lean corporate center.

12. How Does Xeris Biopharma Operate?

On a day-to-day basis, Xeris operates as a specialty pharmaceutical company with an outsourced-manufacturing model and a focused commercial engine.

Product development. Xeris identifies molecules or indications where its formulation science can improve usability, stability, or dosing convenience.
Regulatory and clinical execution. The company manages clinical development, label maintenance, safety monitoring, and ongoing regulatory obligations for approved products and pipeline assets.
External manufacturing oversight. Rather than relying on a giant internal plant network, Xeris coordinates with third-party suppliers for active ingredients, fill-finish work, packaging, testing, and logistics.
Commercial execution. Sales representatives, medical affairs teams, patient-support functions, and reimbursement specialists work to move prescriptions from physician intent to paid therapy.
Lifecycle and portfolio management. Management has to continuously balance support for current brands with investment in new programs such as XP-8121.

The major operating bottlenecks are not unusual for a company of this size: patient diagnosis in rare diseases, payer access, supply continuity, gross-to-net management, and the need to spread fixed commercial costs across a still-limited revenue base.

13. What Are the Growth Opportunities for Xeris Biopharma?

The most plausible growth opportunities for Xeris, based on public evidence through FY2024, are the following:

Further Gvoke penetration. Xeris can still grow if more at-risk diabetes patients are prescribed ready-to-use rescue glucagon instead of relying on older kits or going without a rescue product.
Recorlev expansion. Recorlev appears to have meaningful runway if Xeris can improve diagnosis, referral, and conversion in endogenous Cushing’s syndrome.
Keveyis optimization. Even in a small market, better patient identification and adherence can support incremental growth and steady cash flow.
XP-8121 progression. If once-weekly subcutaneous levothyroxine advances successfully, it could give Xeris a larger commercial opportunity than its current orphan products.
Platform monetization. XeriJect and XeriSol create optionality for internal programs, reformulations, and licensing deals.
Selective M&A or in-licensing. Xeris could add adjacent specialty assets that fit its endocrinology or rare-disease commercial footprint.

The main constraints are equally clear: narrow patient populations, competition in Cushing’s syndrome and glucagon rescue, payer friction, supplier concentration risk, and the need to fund growth without overextending the balance sheet.

14. What Is the History of Xeris Biopharma?

Xeris was founded in 2005 in Chicago and originally built around formulation technologies intended to solve stability and usability problems in injectable medicines.

2005: Xeris was founded and began developing its ready-to-use formulation technologies.
2018: The company completed its initial public offering, giving it access to public-market capital for commercialization and development.
2019: The U.S. Food and Drug Administration approved Gvoke pre-filled syringe, moving Xeris into the commercial stage.
2020: Gvoke HypoPen approval expanded the glucagon franchise with a more user-friendly auto-injector format.
2021: Xeris acquired Strongbridge Biopharma. This was the company’s most important strategic transaction because it added Keveyis and the asset that became Recorlev, while also leading to the current Xeris Biopharma Holdings structure.
Late 2021: Recorlev received FDA approval, further broadening the portfolio.
2022 through FY2024: The company focused on integrating the portfolio, scaling three marketed brands, advancing XP-8121, and improving profitability.

15. What Are the Key Suppliers to Xeris Biopharma?

Suppliers matter strategically to Xeris because it relies heavily on third parties for manufacturing, device components, packaging, testing, and logistics. The most important supplier categories are:

Active pharmaceutical ingredient suppliers for the drug substances used in Gvoke, Recorlev, and Keveyis
Device and component suppliers for the auto-injector or syringe-based presentations used in the Gvoke franchise
Contract manufacturing organizations for formulation, fill-finish, packaging, and batch production
Analytical and quality-service providers for testing, stability work, and release support
Third-party logistics and specialty distribution partners that move product into retail and specialty channels

For Xeris, supplier structure matters less because of raw-material bargaining power and more because of regulatory compliance, reliability, and capacity. A disruption at a limited-source supplier can quickly become a commercial problem, especially for a company with a concentrated product portfolio.

16. What Are the Key Brands Owned by Xeris Biopharma?

Product brands matter more at Xeris than the corporate brand does. The most important brands are:

Gvoke. Positioned around ready-to-use rescue treatment for severe hypoglycemia. The brand’s value proposition is simplicity and immediate usability.
Recorlev. Positioned as a specialist endocrine therapy for endogenous Cushing’s syndrome. The brand competes on clinical utility, specialist focus, and patient-management support.
Keveyis. A rare-disease brand with a small but defensible niche in primary periodic paralysis.
XeriJect and XeriSol. These are technology brands rather than consumer-facing therapy brands. Their role is to signal formulation capability to investors, partners, and potential counterparties.

In strategic terms, Xeris is a product-brand company, not a consumer packaged goods company. Trust with specialists, patients, and channel partners matters more than broad household-name recognition.

17. How Does the Supply Chain of Xeris Biopharma Function?

Xeris’s supply chain is typical of a small specialty pharmaceutical company with outsourced production. The company appears to coordinate rather than fully own most of the physical production network.

Sourcing. Xeris sources active ingredients, excipients, device components, and packaging materials through qualified suppliers.
Manufacturing and fill-finish. Contract manufacturers handle formulation, filling, assembly, packaging, and release processes under quality oversight.
Inventory planning. Demand forecasting matters because the portfolio is relatively small, channel concentration is meaningful, and pharmaceutical shelf-life constraints can create write-off risk if planning is poor.
Distribution. Gvoke moves through wholesale and retail-pharmacy channels, while Recorlev and Keveyis have more specialty-channel characteristics.
Patient delivery and access. The supply chain effectively extends into reimbursement support and specialty-pharmacy coordination, because patients do not become revenue until product is dispensed and paid for.

Xeris’s ready-to-use formulation approach can also be a supply-chain advantage. Products that avoid reconstitution and support room-temperature stability can simplify handling and support ease of use in the field.

18. What Is the Technology Strategy of Xeris Biopharma?

Technology is central to Xeris’s identity. Its strategy is not to be a broad software or digital-health company; it is to use formulation technology as a competitive and economic lever inside specialty pharmaceuticals.

The two core platforms, XeriJect and XeriSol, are designed to help stabilize and deliver molecules that can be difficult to formulate in conventional aqueous systems. Strategically, that matters for two reasons. First, it can create better product formats for Xeris’s own pipeline and marketed brands. Second, it can create partnering or licensing opportunities if other companies want access to those formulation capabilities.

Technology at Xeris is therefore both an internal enabler and a potential external asset. It is central to competitiveness because it can change the user experience, reduce preparation burden, and open development paths that may not be attractive with standard formulations.

19. What Is the R&D Strategy of Xeris Biopharma?

Xeris’s R&D strategy appears more applied and translational than discovery-heavy. The company is not trying to outspend large pharmaceutical companies in basic science. Instead, it is trying to identify validated molecules or disease areas where formulation science can materially improve the product proposition.

That makes XP-8121 a useful example. Rather than inventing a new endocrine biology, Xeris is trying to improve how a known hormone therapy is delivered and dosed. More broadly, Xeris’s R&D work combines formulation engineering, device development, clinical testing, and regulatory execution. Human factors, stability, and manufacturability are especially important because usability is part of the company’s value proposition.

This strategy can be capital-efficient relative to high-risk discovery, but it still requires disciplined prioritization. For Xeris, the real question is how many platform-enabled programs it can fund while still scaling the current commercial portfolio.

20. What Is the Finance Strategy of Xeris Biopharma?

Xeris’s finance strategy through FY2024 appeared to center on turning a growing specialty-pharma revenue base into better operating leverage while preserving enough liquidity to fund targeted development and commercial investment. In practical terms, that means:

Prioritizing revenue growth from marketed brands so that fixed commercial and corporate costs are spread across a larger base
Maintaining discipline on R&D spend by focusing on a narrower set of pipeline opportunities with clearer strategic fit
Managing working capital carefully because inventory, receivables, channel reserves, and gross-to-net adjustments materially affect cash
Using capital allocation to support the core strategy rather than paying dividends or pursuing large-scale shareholder distributions

For a company of Xeris’s size, finance strategy is closely tied to commercial execution. If Gvoke, Recorlev, and Keveyis scale efficiently, the business becomes more self-funding. If not, the balance between growth investment and liquidity becomes tighter.

21. What Major Acquisitions Has Xeris Biopharma Made?

Xeris has not been a high-frequency serial acquirer. The one transformative deal in its modern history was the acquisition of Strongbridge Biopharma in 2021.

That transaction mattered because it changed the company’s strategic profile. Before the deal, Xeris was primarily associated with Gvoke and its formulation platform. After the deal, it had a broader rare-disease and endocrinology portfolio, including Keveyis and the asset that became Recorlev. The acquisition also helped reshape the company into Xeris Biopharma Holdings, Inc.

Viewed strategically, the Strongbridge acquisition was less about scale for its own sake and more about portfolio diversification, commercial leverage, and moving from a one-brand story to a multi-brand specialty-pharma model. As of FY2024, M&A appeared to be a selective tool for Xeris rather than the core engine of growth.

22. How Companies Like Xeris Biopharma Leverage Independent Consultants through Umbrex

Companies like Xeris use independent consultants when they need highly specialized problem-solving without hiring a full consulting team. Umbrex has grown a global community of over 8,000 independent management consultants based in more than 50 countries. These consultants are alums of McKinsey, Bain, BCG, and other top consulting firms. For a company like Xeris, that means access to senior talent across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI for focused projects tied to current strategic priorities.

Portfolio strategy review across Gvoke, Recorlev, Keveyis, and XP-8121 to help management prioritize capital and management attention.
Rare-disease patient-finding strategy to improve diagnosis, referral pathways, and treatment conversion in endogenous Cushing’s syndrome and primary periodic paralysis.
Gvoke commercial acceleration project focused on prescriber segmentation, field-force effectiveness, payer access, and pharmacy pull-through.
Specialty-pharmacy and patient-services redesign to improve prior authorization workflows, onboarding, adherence, and time to therapy start.
Gross-to-net optimization to analyze payer contracting, copay assistance, channel deductions, and net-price realization by product.
XP-8121 launch planning including market sizing, target product profile testing, pricing scenarios, and launch-readiness planning.
Technology-platform partnering strategy for XeriJect and XeriSol, including partner screening, valuation logic, and deal-structure options.
Supply-chain resilience assessment covering contract-manufacturing risk, dual-sourcing priorities, inventory policy, and quality-governance processes.
Operating-model and SG&A productivity work to improve profitability as the company scales from a small portfolio to a broader commercial platform.
Bolt-on acquisition screening and integration support for future specialty-pharma assets that fit Xeris’s endocrinology and rare-disease focus.